While the degree of MLH1 protein reduction was roughly equivalent between pharmacological inhibition and siRNA knockdown of ABL1 in HEK293 cells, we cannot rule out the possibility that either c-Kit or PDGFR may influence MMR in specific tumor backgrounds where they are highly expressed or mutated. The gene discussed is ABL1; the disease is neoplasm.